Article
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Molecular cancer therapeutics - 1 Mar 2011
Janku Filip, Tsimberidou Apostolia M, Garrido-Laguna Ignacio, Wang Xuemei, Luthra Rajyalakshmi, Hong David S, Naing Aung, Falchook Gerald S, Moroney John W, Piha-Paul Sarina A, Wheler Jennifer J, Moulder Stacy L, Fu Siqing, Kurzrock Razelle
Abstract excerpt
Preclinical data suggest that PIK3CA mutations predict response to PI3K/AKT/mTOR inhibitors. Concomitant KRAS or BRAF mutations may mediate resistance. Therefore, tumors from patients referred to the phase I program for targeted therapy starting in October 2008 were analyzed for PIK3CA mutations using PCR-based DNA sequencing of exons 9 and 20. Consecutive patients with diverse tumor types and PIK3CA mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.